Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Shattuck Labs (STTK)
NASDAQ:STTK
Holding STTK?
Track your performance easily
STTK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.94 - $11.76
Previous Close$1.1
Volume113.26K
Average Volume (3M)616.32K
Market Cap
$52.51M
Enterprise Value-$34.80M
Total Cash (Recent Filing)$90.06M
Total Debt (Recent Filing)$2.74M
Price to Earnings (P/E)―
Beta2.62
Next Earnings
Mar 18, 2025EPS Estimate
-$0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding47,739,708
10 Day Avg. Volume302,234
30 Day Avg. Volume616,321
Standard Deviation0.47
R-Squared0.04
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.55
Price to Sales (P/S)8.46
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-5.41
Enterprise Value/Gross Profit-21.00
Enterprise Value/Ebitda0.49
Forecast
1Y Price Target
$2.00Price Target Upside81.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Shattuck Labs News
PremiumCompany Announcements
Shattuck Labs Focuses on Promising Antibody Development
PremiumCompany Announcements
Shattuck Labs Refocuses Strategy Amidst Restructuring and CutsBulls Say, Bears Say
Bulls Say
Financial StabilityShattuck ended the quarter with $90.1 million in cash, which management believes provides runway for all ongoing operations into 2027.
Market OpportunityWith increasing U.S. IBD prevalence and projected worldwide IBD sales reaching $26.8 billion by 2028, a favorable landscape is foreseen.
Product DevelopmentThe company is developing an early pipeline of potentially first-in-class DR3 mono- and bi-specific antibodies in IBD and other autoimmune diseases.
Bears Say
Competitive ChallengesThe competitive landscape in inflammatory bowel disease is intense, with at least seven TL1A-targeting programs already in development.
Program DiscontinuationThe company has discontinued the SL-172154 program in HR-MDS/AML due to lack of significant overall survival benefits compared to historical treatments.
Workforce ReductionManagement has announced a major restructuring, including a 40% reduction in workforce, as part of a strategic pivot.
---
Ownership Overview
19.32% Insiders
18.55% Mutual Funds
35.25% Other Institutional Investors
18.63% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
STTK FAQ
What was Shattuck Labs’s price range in the past 12 months?
Shattuck Labs lowest stock price was $0.94 and its highest was $11.76 in the past 12 months.
What is Shattuck Labs’s market cap?
Currently, no data Available
When is Shattuck Labs’s upcoming earnings report date?
Shattuck Labs’s upcoming earnings report date is Mar 18, 2025 which is in 86 days.
How were Shattuck Labs’s earnings last quarter?
Shattuck Labs released its earnings results on Nov 14, 2024. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.417 by $0.087.
Is Shattuck Labs overvalued?
According to Wall Street analysts Shattuck Labs’s price is currently Undervalued.
Does Shattuck Labs pay dividends?
Shattuck Labs does not currently pay dividends.
What is Shattuck Labs’s EPS estimate?
Shattuck Labs’s EPS estimate is -$0.32.
How many shares outstanding does Shattuck Labs have?
Shattuck Labs has 47,739,708 shares outstanding.
What happened to Shattuck Labs’s price movement after its last earnings report?
Shattuck Labs reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.417. Following the earnings report the stock price went up 12.295%.
Which hedge fund is a major shareholder of Shattuck Labs?
Currently, no hedge funds are holding shares in STTK
---
Shattuck Labs Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.00 (81.82% Upside)
$2.00 (81.82% Upside)
Blogger Sentiment
Neutral
STTK Sentiment 50%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $44.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.00%
12-Months-Change
Fundamentals
Return on Equity
-71.09%
Trailing 12-Months
Asset Growth
-14.36%
Trailing 12-Months
Company Description
Shattuck Labs
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. The company's product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
---
STTK Earnings Call
Q3 2023
0:00 / 0:00
---
STTK Stock 12 Month Forecast
Average Price Target
$2.00
▲(81.82% Upside)
Technical Analysis
Best Analysts Covering STTK
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-52.04%
assigned a buy rating last month
Copying Marc Frahm's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -52.04% per trade.
---